0

ASPIRE-HF: our Phase 2a HFrEF study is enrolling soon →

Skip to Content
Thryv Therapeutics
Thryv Team
Board of Directors
Medical and Scientific Advisors
Investors
Join Us
SGK1 Inhibition
Pipeline
Publications and Presentations
Clinical Studies
Heart Failure
Long QT Syndrome
Atrial Fibrillation
News
Shared Stories & Blog
Contact
Canada: English
Canada: Français
United States
Thryv Therapeutics
Thryv Team
Board of Directors
Medical and Scientific Advisors
Investors
Join Us
SGK1 Inhibition
Pipeline
Publications and Presentations
Clinical Studies
Heart Failure
Long QT Syndrome
Atrial Fibrillation
News
Shared Stories & Blog
Contact
Canada: English
Canada: Français
United States
Folder: About
Back
Thryv Team
Board of Directors
Medical and Scientific Advisors
Investors
Join Us
Folder: Science
Back
SGK1 Inhibition
Pipeline
Publications and Presentations
Clinical Studies
Folder: Focus Areas
Back
Heart Failure
Long QT Syndrome
Atrial Fibrillation
Folder: News & Blog
Back
News
Shared Stories & Blog
Contact
Folder: Region
Back
Canada: English
Canada: Français
United States

Pioneering next-generation precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies

999 Blvd. De Maisonneuve West, Suite 1250
Montréal, Québec

admin@thryvtrx.com

+1 (514) 973-0915


Thryv Australia‍ ‍Privacy Policy‍ ‍Terms of Use

© 2026 Thryv Therapeutics Inc.